All In Biotech

Drug Trial Radar · NCT05515536

A Study to Assess the Safety and Efficacy of Vatiquinone in Participants With Friedreich Ataxia

Long-Term Open-Label Study to Assess the Safety and Efficacy of Vatiquinone in Patients With Friedreich Ataxia

Last checked: Nov 20, 2026Latest source record: Oct 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

130

Actual

Start

Dec 8, 2022

Primary completion

Dec 31, 2027

Study completion Dec 31, 2027

Sponsor

Lead sponsor
PTC TherapeuticsIndustry
Sponsor type
Industry
First posted
Aug 25, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to assess the long-term safety of vatiquinone in participants with Friedreich ataxia (FA) previously exposed to vatiquinone.

Conditions

  • Friedreich Ataxia

Interventions

  • VatiquinoneDrug

    Vatiquinone will be administered per dose and schedule specified in the arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse Events (AEs)Time frame: Baseline up to 3 years

Locations

14 sites in 9 countries. Site status is shown where the registry gives one.

  • UCLA

    Los Angeles, California

  • University of Florida

    Gainesville, Florida

  • University of South Florida

    Tampa, Florida

  • University of Iowa

    Iowa City, Iowa

  • The Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • Murdoch Children's Research Institute

    Parkville, Victoria, Australia

  • University of Campinas (UNICAMP) - School of Medical Sciences, Dept of Neurology

    São Paulo, Brazil

  • Centre de Recherche du Centre Hospitalier de l'Université de Montreal (CRCHUM)

    Montreal, Quebec, Canada

  • CHU Sainte-Justine

    Montreal, Quebec, Canada

  • Hôpital Pitié-Salpêtrière, Institut du Cerveau (Paris Brain Institute)

    Paris, France

  • Department of Neurology and Hertie-Institute for Clinical Brain Research German Center of Neurodegenerative Diseases (DZNE)

    Tübingen, Germany

  • Ospedale Pediatrico Bambino Gesu' IRCCS

    Roma, Italy

  • CBR Neurogenetic Research Clinic, University of Auckland

    Auckland, New Zealand

  • Hospital Sant Joan de Déu Barcelona Unidad de Enfermedades Neuromusculares

    Barcelona, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.